14 June
2023
4basebio PLC
("4basebio" or the "Company")
Annual General Meeting 2023 ("AGM")
4basebio Plc (AIM: 4BB), an innovation driven biotechnology
company enabling and accelerating development of advanced therapy
medicinal products (ATMPs) through its high performant synthetic
DNA products and non-viral, cell targeting nucleic acid delivery
platform announces that all of the resolutions proposed at its
Annual General Meeting held earlier today were duly passed.
The Company also wishes to again draw attention to the investor
meeting being held on 16 June 2023, through the Investor
Meet Company platform at 10.00am. Investors can sign up
to Investor Meet Company for free and register interest
here:
https://www.investormeetcompany.com/register-investor
For further enquiries, please
contact:
4basebio
PLC
+44 (0)12 2396 7943
Heikki Lanckriet
Nominated
Adviser
+44 (0)20 7213 0880
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson
Broker
+44 (0)20 7220 0500
finnCap Ltd
Geoff Nash/Richard Chambers/Charlotte Sutcliffe
Lionsgate Communications (Media
Enquiries)
+44 (0)77 91892509
Jonathan Charles
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life
biotechnology company focussed on accelerating the development of
advanced therapy medicinal products (ATMPs) through its high
performant synthetic DNA products and non-viral, cell targeting
nucleic acid delivery platform. The Company’ objective is to become
a market leader in the manufacture and supply of high quality
synthetic DNA products for research, therapeutic and
pharmacological use as well as development of target specific
non-viral vectors for the efficient delivery of payloads in
patients. The company is offering GMP compliant DNA starting
materials suitable for use in AAV viral vector production as well
as mRNA vaccine and therapeutics production.